This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Petkovic, V. Articles by Mullis, P. E. Search for Related Content PubMed PubMed Citation Articles by Petkovic, V. Articles by Mullis, P. E. Related Collections Neuroendocrinology and Pituitary Pediatric Endocrinology

Evaluation of the Biological Activity of a Growth Hormone (GH) Mutant (R77C) and Its Impact on GH Responsiveness and Stature

Department of Pediatric Endocrinology, Diabetology, and Metabolism (V.P., A.B., D.L., A.E., C.E.F., P.E.M.), University Children’s Hospital, Inselspital, CH-3010 Bern, Switzerland; and Center for Preventive Doping Research-Institute of Biochemistry (M.T.), German Sport University Cologne, 50933 Cologne, Germany

Address all correspondence and requests for reprints to: Professor Dr. Primus E. Mullis, University Children’s Hospital, Pediatric Endocrinology, Inselspital, CH-3010 Bern, Switzerland. E-mail: primus.mullis{at}insel.ch.

Context and Objective: A single missense mutation in the GH-1 gene converting codon 77 from arginine (R) to cysteine (C) yields a mutant GH-R77C peptide, which was described as natural GH antagonist.

Design, Setting, and Patients: Heterozygosity for GH-R77C/wt-GH was identified in a Syrian family. The index patient, a boy, was referred for assessment of his short stature (–2.5 SD score) and partial GH insensitivity was diagnosed. His mother and grandfather were also carrying the same mutation and showed partial GH insensitivity with modest short stature.

Interventions and Results: Functional characterization of the GH-R77C was performed through studies of GH receptor binding and activation of Janus kinase 2/Stat5 pathway. No differences in the binding affinity and bioactivity between wt-GH and GH-R77C were found. Similarly, cell viability and proliferation after expression of both GH peptides in AtT-20 cells were identical. Quantitative confocal microscopy analysis revealed no significant difference in the extent of subcellular colocalization between wt-GH and GH-R77C with endoplasmic reticulum, Golgi, or secretory vesicles. Furthermore studies demonstrated a reduced capability of GH-R77C to induce GHR/GHBP gene transcription rate when compared with wt-GH.

Conclusion: Reduced GH receptor/GH-binding protein expression might be a possible cause for the partial GH insensitivity with delay in growth and pubertal development found in our patients. In addition, this group of patients deserves further attention because they could represent a distinct clinical entity underlining that an altered GH peptide may also have a direct impact on GHR/GHBP gene expression causing partial GH insensitivity.

This article has been cited by other articles:

				V. Petkovic, D. Lochmatter, J. Turton, P. E. Clayton, P. J. Trainer, M. T. Dattani, A. Eble, I. C. Robinson, C. E. Fluck, and P. E. Mullis Exon Splice Enhancer Mutation (GH-E32A) Causes Autosomal Dominant Growth Hormone Deficiency J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4427 - 4435. [Abstract] [Full Text] [PDF]